Welcome to our dedicated page for LianBio news (Ticker: LIAN), a resource for investors and traders seeking the latest updates and insights on LianBio stock.
LianBio (LIAN) is a pioneering biotechnology company dedicated to accelerating the availability of transformative medicines to patients in China and major Asian markets. The company's mission involves forging partnerships with world-class biopharmaceutical firms to bring paradigm-shifting therapies to historically underserved regions.
Core Business: LianBio focuses on building a diversified portfolio of drug candidates that address significant unmet medical needs. The company's therapeutic focus spans multiple areas, including cardiovascular, oncology, ophthalmology, and inflammatory diseases. They employ a strategy of precision-based therapeutics and transformative mechanisms to impact patient outcomes substantially.
Recent Achievements: LianBio has been making notable strides in clinical development and regulatory milestones. Their product infigratinib, an ATP-competitive FGFR1-3 selective oral tyrosine kinase inhibitor, has shown promising results in a Phase 2 clinical trial for gastric cancer and gastroesophageal junction adenocarcinoma. The study demonstrated a confirmed objective response rate (cORR) of 23.8% and a disease control rate (DCR) of 76.2%, among other encouraging metrics. Infigratinib has received Breakthrough Therapy Designation from the China National Medical Products Administration (NMPA).
Current Projects: In addition to infigratinib, LianBio is advancing the clinical development of TP-03, a novel eye drop treatment for Demodex blepharitis. The Phase 3 LIBRA trial demonstrated significant mite eradication, positioning TP-03 for potential regulatory approval in China. The company is also involved in the Phase 1 clinical trial of BBP-398, a SHP2 inhibitor in combination with EGFR inhibitor osimertinib for non-small cell lung cancer (NSCLC) patients.
Financial Condition: For the third quarter of 2023, LianBio reported research and development expenses of $9 million and general and administrative expenses of $17.3 million. The company’s net loss for the same period was $24 million. Despite these expenditures, LianBio maintains a robust cash balance of $252.2 million, ensuring financial stability for ongoing and future projects.
Partnerships: LianBio collaborates with several high-caliber global biopharmaceutical companies, enhancing their capability to bring innovative treatments to market. Notably, they have licensed rights from QED Therapeutics and Tarsus Pharmaceuticals to develop and commercialize breakthrough therapies in China and other Asian territories.
Future Outlook: The company is currently undergoing a strategic review aimed at maximizing shareholder value, including the potential sale of pipeline assets and workforce reductions. LianBio continues to focus on providing access to innovative medicines, leveraging its international infrastructure and strategic partnerships to address critical health needs in the region.
For the latest updates and more detailed information, please visit www.lianbio.com.
LianBio (LIAN) announced the completion of enrollment in the Phase 3 EXPLORER-CN trial for mavacamten, a treatment for hypertrophic cardiomyopathy, with data expected in mid-2023. In China, they initiated pivotal trials for TP-03 and NBTXR3, targeting Demodex blepharitis and head & neck cancer, respectively. LianBio reported a cash balance of $331.8 million as of September 30, 2022, with a runway extending into the second half of 2024. The company aims to launch its first product in 2024, marking significant progress in its clinical pipeline.
LianBio (Nasdaq: LIAN), a biotechnology company focused on innovative medicines for China and Asia, announced participation in several key conferences from November 14-18, 2022. Events include the BioCentury-BayHelix East-West Biopharma Summit, Goldman Sachs Asia Pacific Healthcare Forum, and Jefferies London Healthcare Conference. Notable sessions feature discussions on biotech and capital markets, alongside company presentations and 1:1 meetings. A live audio webcast will be available for the Jefferies conference via LianBio’s investor website.
LianBio (Nasdaq: LIAN) has initiated a Phase 1 clinical trial of BBP-398, a SHP2 inhibitor, in Chinese patients with advanced solid tumors. This two-part study will assess safety, pharmacokinetics, and preliminary anti-tumor activity. Targeting the overactive SHP2 protein, which contributes to cancer resistance, BBP-398 aims to enhance treatment for patients, particularly those with EGFR-mutant non-small cell lung cancer (NSCLC). The company also plans to explore BBP-398 in combination with EGFR inhibitors, with trials expected to begin in 2023.
LianBio (Nasdaq: LIAN) announced the dosing of the first patient in the Phase 3 LIBRA clinical trial for TP-03, targeting Demodex blepharitis in China. With an estimated 43 million patients affected, there are currently no approved treatments in China or the U.S. TP-03 demonstrated significant results in prior U.S. trials, meeting all primary and secondary endpoints. The LIBRA trial aims to enroll 162 patients, with topline results expected in Q4 2023, potentially setting a new standard of care for this condition.
Nanobiotix announced operational progress in its pivotal Phase 3 study, NANORAY-312, focusing on elderly patients with locally advanced head and neck cancer. The first patient has been enrolled in Asia, with plans to recruit approximately 100 patients globally. Financially, the company reported €63 million in cash equivalents as of June 30, 2022, and expects funding through Q1 2024 due to a debt restructuring with the EIB. Despite a stable revenue of €1.3 million, R&D expenses rose to €16.6 million. The net loss decreased to €26.4 million, or €0.76 per share, compared to €30.4 million in 2021.
Nanobiotix and LianBio have announced the enrollment of the first patient in the pivotal Phase 3 NANORAY-312 trial for NBTXR3, targeting elderly patients with locally advanced head and neck cancer ineligible for platinum-based chemotherapy. This trial will assess the effectiveness of NBTXR3 combined with radiotherapy and cetuximab. With a global enrollment goal of 500 patients, LianBio aims to enroll approximately 100 in Asia. Previous trials show promising survival rates, positioning NBTXR3 as a potential key treatment in a rapidly growing radiotherapy market in Asia.
LianBio (Nasdaq: LIAN) reported significant progress in its clinical development and regulatory submissions as of August 11, 2022. The company completed enrollment in the Phase 3 EXPLORER-CN trial of mavacamten in China, with topline data expected in mid-2023. LianBio submitted New Drug Applications for both mavacamten and infigratinib in Singapore and Hong Kong, respectively. Despite COVID-19 disruptions, cash reserves stood at $349.4 million, providing a runway into mid-2024. The firm anticipates launching three additional registration-enabling programs in China by year-end 2022.
LianBio (Nasdaq: LIAN) has completed enrollment in the Phase 3 EXPLORER-CN clinical trial for mavacamten, targeting symptomatic obstructive hypertrophic cardiomyopathy in Chinese patients. Despite COVID-related challenges, patient enrollment was rapid, reflecting strong demand for new therapies. Topline data is expected in mid-2023, which, if positive, will aid in a New Drug Application submission in China. Mavacamten has already received Breakthrough Therapy Designation in China and was FDA-approved in the U.S. for similar indications, highlighting its potential market impact.
LianBio (Nasdaq: LIAN) announced participation in upcoming investor conferences, including the Jefferies Healthcare Conference on June 10, 2022, and the Goldman Sachs Healthcare Conference on June 15, 2022. Both events will feature live audio webcasts accessible via the company's website. LianBio focuses on delivering innovative medicines to patients in China and other major Asian markets, advancing a diversified portfolio of product candidates across various therapeutic areas such as cardiovascular, oncology, and more.
FAQ
What is the market cap of LianBio (LIAN)?
What is LianBio’s mission?
What therapeutic areas does LianBio focus on?
What recent clinical achievements has LianBio made?
What is TP-03?
Who are LianBio's key partners?
What is LianBio's financial outlook?
What is infigratinib?
What markets does LianBio serve?
How is LianBio's management adapting to recent changes?